News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Biogen
NEWS
JOBS
IN THE PRESS
NEWS
Deals
Why Merck & Co. and Allergan Won’t Buy Biogen
November 4, 2016
·
4 min read
Genetown
Why Biogen, bluebird bio and Xencor are 3 Stocks to Look at in November
November 3, 2016
·
2 min read
Deals
Here’s Why Biogen Should Buy Ionis Pharma
November 1, 2016
·
2 min read
Genetown
The Good (Celgene) And Bad (Biogen) Ways To Deliver Drug Revenue Growth
October 28, 2016
·
1 min read
Genetown
Novartis AG Is Challenging Biogen On Biogen’s Own Turf
October 27, 2016
·
1 min read
Business
Biogen’s CEO Hunt Holds Company in Limbo
October 27, 2016
·
3 min read
Drug Development
Why Biogen’s Fate May Depend on Eli Lilly’s Alzheimer’s Data
October 27, 2016
·
3 min read
Genetown
Biogen Quietly Kills Autoimmune Program
October 26, 2016
·
3 min read
Business
Biogen Could Add $1 Billion In 2017 On Muscular Dystrophy Drug
October 25, 2016
·
1 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
·
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
·
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
·
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
·
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
·
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
·
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
·
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
·
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
·
32 min read
Press Releases
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026
·
13 min read
